Article Text

Download PDFPDF
706 Borderline ovarian tumours: diagnostic and therapeutic difficulties (about 12 cases)
  1. Naima Laiche,
  2. Fatima Zohra Fdili Alaoui,
  3. Yassine Belhaj,
  4. Sofia Jayi,
  5. Hekmat Chaara and
  6. Moulay Abdelilah Melhouf
  1. Centre Hospitalier Universitaire Hassan II, Fez, Morocco


Introduction/Background Borderline ovarian tumours (BOT) account for 15% to 20% of epithelial ovarian tumours. Diagnosis is histological and treatment should be as conservative as possible in the early stages in young patients. The aim of our work is to take stock of the difficulties of clinical, para-clinical and histological diagnosis and to evaluate the prognosis in order to determine a therapeutic protocol.

Methodology We conducted a retrospective study of 12 cases of BOT, collected in the department of gynaecology-obstetrics 2- CHU Hassan II of Fez, during a period of 4 years from 2020 to 2023.

Results The mean age of our patients was 47 years, ranging from 22 to 67 years. 16% were nulliparous. Pelvic pain was the reason for consultation in all our patients, with an increase in abdominal volume in 33% of cases. 80% of patients had a palpable abdominopelvic mass. Ultrasound was performed in all our patients and allowed the pelvic mass to be related to its adnexal origin in 75% of cases, with bilateral location in 33% of cases and a size ranging from 5 cm to 40 cm. 83% of our patients underwent CT and 27% benefited from MRI, with a radio-histological concordance of 25%. Given the unavaibility of laparoscopy, all patients underwent exploratory laparotomy. Treatment was radical in 42% of cases and conservative in 58%. Serous BOT was the predominant histological type in 67% of patients; 33% of cases had a mucinous tumour. Eight patients completed follow-up in the gynaecology department with a favourable clinical and radiological outcome. One case, whom received chemotherapy, was referred to oncology. Three patients were lost to follow-up.

Conclusion BOT generally affects young patients for whom fertility preservation is an important therapeutic consideration. The prognosis is excellent, with a 5-year survival rate of 95%.

Disclosures The authors have no conflicts of interest to declare. there was no funding for this study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.